The EEDS, a Key Element for European Research

The development of the European Health Data Space (EEDS) could become a key element for “facing future health challenges more quickly” within a European Union that must face its immediate future after overcoming the health crisis caused by the pandemic.

This was stated by several of the experts who participated this Tuesday, November 15th, in the meeting ‘Dialogues with Europe. A shared vision of the future in healthcare’ organized by Boehringer Ingelheim and whose objective is to present a series of reflections on the new European Health Union.

Read more on the subject and find other important economic news from around the world with the Born2invest mobile app.

In this context, the role that the EEDS can play as a unifying and cohesive element of a fully integrated continental system was analyzed at the second round table of the day

The new healthcare information and data environment that Europe intends to develop “will be the driving force behind healthcare research, the development of digital technologies and new treatments,” said Ana López de la Rica, associate director of Farmaindustria’s Technical Department, who also pointed out the system’s capacity to “detect healthcare trends” in the face of possible new crises that may arise on the continent.

On the other hand, the EEDS is a network of nodes that have data, “it is not an immense repository”, said Lucia Escapa, head of the technical office of the General Secretariat for Digital Health, who also explained that this network of nodes means that every time information is sought it will be necessary to pass a filter that justifies it.

Escapa also advocated the importance of “explaining to the public” the importance of sharing data and the advantage that, through the knowledge acquired, this will be passed on to the healthcare systems of each country.

The functioning of the system is “fully guaranteeing data protection”, assured Susana Solís, MEP, substitute member of the Committee on the Environment and Public Health, also affirming that the future of the EEDS is to become “a very important pillar” of the Europe of Health.

Patients “are excited” about this project; at least this is what Pedro Carrascal, Director General of the Platform of Patients’ Organizations (POP), assures, who considers that with the EEDS “we are going to win in Health”.

Together with the EEDS, the EU must also take on other new challenges in its healthcare policies, and precisely conferences like this one “allow us to be aware of the context and understand the different points of view in order to create synergies”, according to Concha Marzo, Director of Government Affairs at Boheringer Ingelheim.

The ambassador to the Special Mission for the International Crisis of Covid, of the Ministry of Foreign Affairs, Borja Cabezón, pointed out that precisely crises such as the current one have made it possible to “speed up” the European Union’s decision-making processes.

This assessment was shared by the Director of the Representation of the European Commission in Spain, María Ángeles Benítez, who assured that “the current problems have reached such a level of complexity that they require the collaboration of all to face them.”

__

(Featured image by hpgruesen via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in diariofarma, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.